This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include: Encompass Health, Celanese Corp, Salesforce, Ovintiv and Expeditors International of Washington
by Zacks Equity Research
Zacks.com featured highlights include: Encompass Health, Celanese Corp, Salesforce, Ovintiv and Expeditors International of Washington
Bull Of The Day: Salesforce (CRM)
by Daniel Laboe
This innovation-fueled business continues to grow its total addressable market (TAM) through a combination of synergy driving acquisitions and organic developments that power its unprecedented profitable growth
5 Top Stocks With Impressive Sales Growth to Buy Right Away
by Swayta Shah
Sales growth is important for the survival of any business. Let's check Encompass Health (EHC), Celanese (CE), salesforce.com (CRM), Ovintiv (OVV) & Expeditors International (EXPD) that are likely to witness solid top-line growth.
Salesforce.com (CRM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Salesforce.com (CRM) closed at $247.60 in the latest trading session, marking a -0.26% move from the prior day.
Cognizant (CTSH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Cognizant's (CTSH) second-quarter results are likely to reflect steady demand in digital engineering, cloud and IoT, partially offset by weakness across select global banking accounts.
Salesforce's (CRM) $27.7B Slack Buyout Deal Nears Closure
by Zacks Equity Research
In an 8-K filing with the Securities And Exchange Commission on Jul 19, Salesforce (CRM) revealed that the Department of Justice has closed its antitrust probe into the Slack's acquisition deal.
Salesforce.com (CRM) Stock Moves -0.37%: What You Should Know
by Zacks Equity Research
Salesforce.com (CRM) closed at $237.55 in the latest trading session, marking a -0.37% move from the prior day.
Salesforce.com (CRM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Salesforce.com (CRM) closed at $244.02, marking a +0.46% move from the previous day.
Salesforce.com (CRM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Salesforce.com (CRM) closed at $248.44, marking a -0.72% move from the previous day.
The Zacks Analyst Blog Highlights: Salesforce, Thermo Fisher Scientific, Royal Dutch Shell, Citigroup and Starbucks
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Salesforce, Thermo Fisher Scientific, Royal Dutch Shell, Citigroup and Starbucks
4 Stocks to Watch Amid Rise in Enterprise Software Spending
by Kaustav Ghosh
Watch out for the likes of ServiceNow (NOW), Salesforce (CRM), Amazon (AMZN) and SAP (SAP) as enterprise software spending looks set to make a comeback this year.
Top Stock Reports for salesforce, Thermo Fisher & Royal Dutch Shell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including salesforce (CRM), Thermo Fisher Scientific (TMO), and Royal Dutch Shell (RDS.A).
Salesforce.com (CRM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Salesforce.com (CRM) closed the most recent trading day at $244.27, moving -0.63% from the previous trading session.
Salesforce (CRM) Issues Senior Notes to Fund Slack Acquisition
by Zacks Equity Research
Salesforce (CRM) is borrowing $8 billion through issuing senior notes to fund the proposed acquisition of Slack Technologies (WORK).
Bull of the Day: Zoom Video (ZM)
by Benjamin Rains
Zoom has diversified its offerings and is poised to thrive in the hybrid work environment. And Wall Street seems to agree ZM has legs beyond the pandemic, with the stock up around 35% since May 10...
Salesforce (CRM) Expands AWS Partnership to Enhance App Development
by Zacks Equity Research
Developers will be able to customize their applications by seamlessly integrating Salesforce (CRM) data and workflows into AWS-backed solutions.
Salesforce (CRM) Enters Key Olympic and Paralympic Partnerships
by Zacks Equity Research
Salesforce's (CRM) technology will be used to create Olympic and Paralympic fan communities, and enhance fan and athlete engagement across digital platforms over the next seven years.
Stock Market News for Jun 16, 2021
by Zacks Equity Research
U.S. stock markets closed lower on Tuesday as investors remained watchful ahead of the U.S. Federal Reserve's two-day policy meeting which began on Tuesday.
The Zacks Analyst Blog Highlights: Salesforce, Shopify, AstraZeneca, Micron and Ecolab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Salesforce, Shopify, AstraZeneca, Micron and Ecolab
Here's How Much You'd Have If You Invested $1000 in Salesforce.com a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Top Research Reports for salesforce, Shopify & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including salesforce.com (CRM), Shopify (SHOP), and AstraZeneca (AZN).
2 Tech Stocks to Buy Now at Big Discounts for Long-Term Growth
by Benjamin Rains
Investors with longer-term horizons might want to buy strong growth-focused stocks prepared to thrive for years to come in the digital age. And why not look for ones that are trading well below their records...
Stock Market News for Jun 7, 2021
by Zacks Equity Research
Benchmarks closed in the green on Friday as lesser-than-expected job additions eased concerns that the Federal Reserve might tighten monetary policies soon
Stock Market News for Jun 1, 2021
by Zacks Equity Research
Wall Street closed Friday on a positive note buoyed by economic data confirming strong U.S. economic recovery from the pandemic despite growing inflationary threat.
Salesforce.com (CRM) Moves 5.4% Higher: Will This Strength Last?
by Zacks Equity Research
Salesforce.com (CRM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.